Vascular EDS, the dangerous subtype

The clinical questions in vascular Ehlers-Danlos syndrome are not which joint hurts and which brace fits. They are which artery, which year, and how prepared the family was when the call came. vEDS is the EDS subtype that kills, and it kills suddenly, and the median age at the killing event is in the thirties or forties depending on the cohort and the specific pathogenic variant.

Vascular EDS is caused by heterozygous variants in COL3A1, the gene encoding the alpha-1 chain of type III collagen. Type III collagen is concentrated in arteries, the bowel, and the gravid uterus. When type III collagen is absent or misassembled, those tissues lose tensile strength, and the events that follow are arterial dissection, arterial rupture, bowel perforation, and uterine rupture during pregnancy. vEDS is autosomal dominant. Roughly half of cases are inherited and half arise from de novo variants.

What the cohort data shows

The largest reported series is the University of Washington COL3A1 cohort, characterized by Pepin and colleagues. Their 2014 paper in Genetics in Medicine analyzed 1,231 affected people from 631 families. Median survival in that cohort was 51 years overall, with mutation type as the strongest predictor: people with COL3A1 null variants (haploinsufficiency, where one allele produces no protein) had a milder course and longer survival than people with structural missense variants that produce abnormal protein. The most common cause of death was arterial rupture, followed by intestinal perforation and pregnancy-related events. Roughly 80 percent of affected individuals had a major complication by age 40.

A separate analysis by Murray, Pepin, Peterson, and Byers in 2014 focused specifically on pregnancy. Across 565 deliveries among 81 women with vEDS, there were 30 pregnancy-related deaths. The death rate of 5.3 percent per delivery captured the risk profile of an era before systematic preconception counseling and managed delivery in experienced centers. A 2026 multicenter retrospective cohort published in BJOG by Bersselaar and colleagues reported lower mortality with modern preconception management, planned cesarean in the late preterm window, and care at experienced centers. Adverse events still occurred.

Diagnosis

Clinical features include thin translucent skin (with visible subcutaneous veins, particularly across the chest), characteristic facial features in some affected individuals, easy bruising, small joint hypermobility (large joints typically not), and a family or personal history of arterial dissection or rupture, sigmoid perforation, or pregnancy-related vascular events. Confirmation is by COL3A1 sequencing. The 2017 international classification specifies that vEDS diagnosis requires either a confirmed pathogenic variant or, in the absence of testing, the combination of major and minor criteria sufficient to warrant the label.

vEDS is reported worldwide, with no known major founder effects. Prevalence estimates run roughly 1 in 50,000 to 1 in 200,000.

What management looks like

There is no FDA-approved disease-specific drug therapy for vEDS. Standard of care is risk reduction and surveillance. Beta-blockers, particularly celiprolol, have been studied for their potential to reduce arterial events. The 2010 BBEST trial in France reported a roughly threefold reduction in arterial events on celiprolol over a median follow-up of 47 months, although the trial was small and the result has not been replicated in a larger randomized study. Practice varies. Many vEDS centers recommend celiprolol or another beta-blocker as part of routine management.

Surveillance imaging includes baseline whole-body magnetic resonance angiography or computed tomography angiography to map the arterial anatomy, with periodic repeat imaging. Identification of incidental aneurysms allows for intervention before rupture in some cases. Vascular intervention in vEDS is technically more difficult than in unaffected people, because the vessel wall is fragile at the puncture and surgical sites and standard techniques can produce iatrogenic dissection. Endovascular and surgical procedures in vEDS are concentrated at experienced centers.

Pregnancy is high-risk. Preconception counseling, multidisciplinary care including maternal-fetal medicine and vascular surgery, planned delivery at a center with experience in vEDS pregnancy, and careful blood pressure management are the documented elements of a managed-pregnancy approach.

Genetic counseling is part of every vEDS encounter. The 50 percent transmission risk to children, the implications for siblings and parents, the question of testing in pregnancy, and the question of testing in children all come up. The clinical-genetic counseling combination is the closest thing vEDS has to a treatment infrastructure.

What this looks like for a family

A 32-year-old woman with vEDS sits down for her first preconception visit at a dedicated center. She has known about her diagnosis since her teens because her mother died at 41 of an aortic dissection, and the family was tested. Her own surveillance imaging at 28 showed a small splenic artery aneurysm that has been stable on follow-up imaging. She is on celiprolol. She wants to have a child. The question on the table is which weeks of pregnancy carry which risks, what the delivery plan looks like, what intensive care unit will be on standby, and which specific cardiothoracic surgeon will be paged if anything goes wrong.

The data she has is the cohort data, the natural history papers, and the published experience of vEDS centers. The data she does not have is what her own arteries are going to do. The medicine for vEDS, today, is more careful planning around an irreducible risk.